Unitaid awards Medincell US$6m to fight malaria
The funding commitment for MedinCell Corp’es reformulation of the antipararsitic ivermectin comes after great progress in malaria vaccines: The...
Bayer's Ask Bio unit starts Phase II heart failure gene therapy
The Phase II trial called GenePHIT is the largest adaptive, double-blind, placebo-controlled, randomised, multicentre trial ever to evaluate the...
PulseSight to disrupt AMD space
Aiming to address the pressing challenges of age-related macular diseases (AMD), including wet and dry AMD, along with geographic atrophy (GA),...
Shock: Adrenomed AG gets FDA fast track designation
After Adrenomed AG has demonstrated that its septic shock treatment led to a 60% reduction in relative 28-day mortality vs. placebo in a stratified...
TME Pharma gets FDA Fast Track for Glioblastoma
TME Pharma N.V. with research sites in France and Germany (listed at Euronext Growth Paris: ALTME) is developing novel therapies for treatment of...
Flindr Therapeutics BV secures €20m Series A financing
The Series A financing was led by V-Bio Ventures and an international syndicate that includes Johnson & Johnson Innovation – JJDC, Inc., QBIC...
EU parliament backs deregulation of New Genome Techniques
With the MEPs' approval of the amendments to the European Commission's draft legislation, the way is now clear for a regulation that distinguishes...